IDO Inhibition Facilitates Antitumor Immunity of Vγ9Vδ2 T Cells in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) escape from immune-mediated destruction was associated with immunosuppressive responses that dampened the activation of tumor-infiltrating CD8 and γδ T cells. TNBC had a higher level of programmed cell death 1-ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase (IDO...
Main Authors: | Peng Li, Ruan Wu, Ke Li, Wenhui Yuan, Chuqian Zeng, Yuting Zhang, Xiao Wang, Xinhai Zhu, Jianjun Zhou, Ping Li, Yunfei Gao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.679517/full |
Similar Items
-
Current Challenges for IDO2 as Target in Cancer Immunotherapy
by: Giada Mondanelli, et al.
Published: (2021-04-01) -
B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells
by: Huimin Lu, et al.
Published: (2020-01-01) -
Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors
by: Michael ePlatten, et al.
Published: (2015-01-01) -
Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO
by: Minah Kim, et al.
Published: (2021-02-01) -
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
by: Asha Nayak-Kapoor, et al.
Published: (2018-06-01)